Sanofi: FDA approves Admelog
(CercleFinance.com) - Sanofi has announced that the Food and Drug Administration (FDA) of the United States has approved Admelog, the first follow-on insulin lispro to help people living with diabetes manage blood sugar levels at mealtimes.
The Admelog clinical development program included over 1,000 adults with type-1 or type-2 diabetes. Admelog will be available in vials and the pre-filled pen SoloStar, the most used disposable insulin Pen model in the United States.
Admelog was also granted marketing authorisation as a biosimilar, under the proprietary name, Insulin lispro Sanofi, by the European Commission in July 2017.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The Admelog clinical development program included over 1,000 adults with type-1 or type-2 diabetes. Admelog will be available in vials and the pre-filled pen SoloStar, the most used disposable insulin Pen model in the United States.
Admelog was also granted marketing authorisation as a biosimilar, under the proprietary name, Insulin lispro Sanofi, by the European Commission in July 2017.
Copyright (c) 2017 CercleFinance.com. All rights reserved.